Financials
Financial year 2025
Perfusion Extracorporeal Technology from Gembloux, company number BE0784827493, closed financial year 2025 with a result of € -6,541 after tax. For that financial year Perfusion Extracorporeal Technology recorded a gross margin of € -3,940 and equity of € 8,736. Compared with financial year 2024, the result moved from € 2,278 to € -6,541. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.
€ 8,736
▼ 43% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -6,541
▼ still € 2,278 profit in 2024
Profit after tax over the fiscal year.
€ 5,999
▼ 19% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 6,736.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 4,913
▲ 126% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 11,973
▲ 167% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 7,982
▲ 3% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 13,859 | € 9,395 | € 6,973 | € -3,940 | ▼ € 10,913 |
| Profit after taxes | € 7,514 | € 3,484 | € 2,278 | € -6,541 | ▼ € 8,820 |
| Equity | € 9,514 | € 12,998 | € 15,277 | € 8,736 | ▼ 43% |
| Total debts | € 9,236 | € 11,855 | € 14,322 | € 24,043 | ▲ 68% |
| Cash | € 4,535 | € 10,800 | € 7,434 | € 5,999 | ▼ 19% |
| Retained profit | € 7,514 | € 10,998 | € 13,277 | € 6,736 | ▼ 49% |
| Balance sheet total | € 18,750 | € 24,853 | € 29,599 | € 32,779 | ▲ 11% |
Key figures of Perfusion Extracorporeal Technology, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Perfusion Extracorporeal Technology?
What happened at Perfusion Extracorporeal Technology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 6,541 (▼ € 8,820 vs 2024). Source: NBB ↗
- New establishment in Gembloux. KBO
- Start of the company according to the CBE. KBO
- Dylan SCHILLINGS became a director. NBB
In short
From € 7,514 profit in 2022 to € 6,541 loss in 2025.
Paid € 7,167 in corporate taxes since 2022.
Best year ever: 2022, with € 7,514 profit.
Management
Behind Perfusion Extracorporeal Technology is Dylan SCHILLINGS.
Directors
According to the 2025 annual accounts
Dylan SCHILLINGS
Administrator-manager
since 2022
Establishments
Establishment units
Physical locations of this company
Rue des Haipes,Sauv. 8
5030 Gembloux
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0784.827.493
- VAT number
- BE 0784.827.493
- Registered office
- Rue des Haipes,Sauv. 8, 5030 Gembloux
- Names & denominations
- Perfusion Extracorporeal Technology · PEx Tech
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 14 April 2022
- Peppol
- Active · Active since 19 Aug 2026
- Activities · NACE
Activiteiten van verpleegkundigen en verloskundigen
Overige zakelijke dienstverlening, neg
Verpleegkundige activiteiten